Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (4615)	10/23/2000 3:58:10 PM
From: scott_jiminez	Respond to of 10280

A study from 1996 appears to supply evidence supporting the Biocentury report ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8831113&dopt=Abstract

To: tommysdad who wrote (4615)	10/23/2000 4:23:16 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 10280

"According to today's Biocentury, R-fluoxetine is actually 8 times less (that's right, less) potent than S-fluoxetine" I think I know what you are referring to. But, I do not believe that discussing "differential duration of action" between S & R and saying that "the R-isomer is less potent than the S-isomer" ... "which led LLY to run its trial of R-fluoxetine using an eight-fold higher dose" is the same. If I do not have this right, would you like to provide an exact quote from Biocentury on which you rely. ij